Advanced Search

Study Preview



Study Title and Description

Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.



Key Questions Addressed
2 Key Question 2. In adult women without preexisting breast cancer, what is the effectiveness and comparative effectiveness of medications to reduce risk for primary breast cancer on improvement in short- and long-term health outcomes, including invasive breast cancer, noninvasive breast cancer (including ductal carcinoma in situ), breast cancer mortality, all-cause mortality, and other beneficial outcomes (such as reduced fractures caused by certain medications and improved quality of life)? Key Question 2a. Does the effectiveness of risk-reducing medications vary by timing of initiation or duration of use? Key Question 2b. Does the effectiveness of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |
3 Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Author Grady D., Cauley JA., Geiger MJ., Kornitzer M., Mosca L., Collins P., Wenger NK., Song J., Mershon J., Barrett-Connor E.
Country University of California, San Francisco, and San Francisco VA Medical Center, San Francisco, CA 94115, USA. deborah.grady@ucsf.edu
Year 2008
Numbers Pubmed ID: 18544744

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-4


Results & Comparisons

No Results found.